A Phase II trial of bryostatin 1 in the treatment of metastatic colorectal cancer

Clinical Cancer Research

Volumn 7, Issue 1, 2001, Pages 38-42

  Zonder, Jeffrey A ^a   Shields, Anthony F ^a   Zalupski, Mark ^a   Chaplen, Ruth ^a   Heilbrun, Lance K ^a   Arlauskas, Patricia ^a   Philip, Philip A ^a  

^a KARMANOS CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRYOSTATIN 1; FLUOROURACIL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER GROWTH; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MYALGIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LACTONES; MACROLIDES; MALE; MIDDLE AGED; NEOPLASM METASTASIS; TREATMENT OUTCOME;

EID: 0035139097     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Cancer of the colon
2. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project
3. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer
4. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer
5. Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: A Phase II multicentric study
6. Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers
7. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy
8. Combined irinotecan and oxaliplatin plus granulocyte colony-stimulating factor in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer
9. The role of protein kinase C in cell surface signal transduction and tumor promotion
10. Protein kinase C
11. The protein kinase C family
12. Potential for protein kinase C inhibitors in cancer therapy
13. Distinct protein kinase C isozymes signal mitogenesis and apoptosis in human colon cancer cells
14. Bryostatin 1 antagonizes the terminal differentiating action of 12-O-tetradecanoylphorbol-13-acetate in a human colon cancer cell
15. Phorbol esters activate proteoglycan metabolism in human colon cancer cells en route to terminal differentiation
16. Overexpression of protein kinase C β1 in the SW480 colon cancer cell line causes growth suppression
17. Overexpression of protein kinase C in HT29 colon cancer cells causes growth inhibition and tumor suppression
18. Modulation of intracellular second messengers by dietary fat during colonic tumor development
19. Pharmacology and clinical experience with bryostatin 1: A novel anticancer drug
20. Bryostatin 1 modulates the proliferation and lineage commitment of human myeloid progenitor cells exposed to recombinant interleukin-3 and recombinant granulocyte-macrophage colony-stimulating factor
21. The action of bryostatin on normal human hematopoietic progenitors is mediated by accessory cell release of growth factors
22. Bryostatins 1, 2 and 5 activate human granulocytes and lymphocytes: In vitro and in vivo studies
23. In vivo administration of the anticancer agent bryostatin 1 activates platelets and neutrophils and modulates protein kinase C activity
24. Bryostatin 1 activates protein kinase C and induces monocytic differentiation of HL-60 cells
25. Varied differentiation responses of human leukemias to bryostatin 1
26. Conversion of high grade lymphoma tumor cell line to intermediate grade with TPA and bryostatin 1 as determined by polypeptide analysis on 2D gel electrophoresis
27. Differential effects of bryostatin 1 and phorbol ester on human breast cancer cell lines
28. Comparison of effects of growth factors and protein kinase C activators on cellular sensitivity to cis-diamminedichloroplatinum(II)
29. Potentiation of 2-chlorodeoxyadenosine activity by bryostatin 1 in the resistant chronic lymphocytic leukemia cell line (WSU-CLL): Association with increased ratios of dCK/5'-NT and Bax/Bcl-2
30. Evidence of a functional role for the cyclin-dependent kinase inhibitor p21(WAF1/CIP1/MDA6) in the reciprocal regulation of PKC activator-induced apoptosis and differentiation in human myelomonocytic leukemia cells
31. Bryostatin 1 down-regulates mdrl and potentiates vincristine cytotoxicity in diffuse large cell lymphoma xenografts
32. Modulation of chemosensitivity in human colon carcinoma cells by downregulating protein kinase Cα expression
33. Inhibition of protein kinase C-α isoform enhances the P-glycoprotein expression and the survival of LoVo human colon adenocarcinoma cells to doxorubicin exposure
34. Phase I study of bryostatin 1: Assessment of interleukin 6 and tumor necrosis factor a induction in vivo. The Cancer Research Campaign Phase I Committee
35. A Phase I study of intravenous bryostatin 1 in patients with advanced cancer
36. A Phase I trial of bryostatin 1 in patients with advanced malignancy using a 24 hour intravenous infusion
37. Phase I study of bryostatin 1 in patients with relapsed non-Hodgkin's Iymphoma and chronic lymphocytic leukemia
38. Phase Ib trial of bryostatin 1 in patients with refractory malignancies
39. Differing roles of protein kinase C on the antiproliferative effects of tumor necrosis factor a and β on LoVo cells
40. Protein kinase C β1 and protein kinase C β2 activate p57 mitogen-activated protein kinase and block differentiation in colon carcinoma cells
41. Induction of ornithine decarboxylase in normal and protein kinase C-depleted human colon carcinoma cells
42. Protein kinase C activation selectively increases mRNA levels for one of the regulatory subunits (RIα) of cAMP-dependent protein kinases in HT-29 cells
43. Agonist-induced desensitization of cholinergically stimulated phosphoinositide breakdown is independent of endogenously activated protein kinase C in HT-29 human colon carcinoma cells
44. Activation of protein kinase C augments butyrate-induced differentiation and turnover in human colonic epithelial cells in vitro
45. Phorbol ester augments butyrate-induced apoptosis of colon cancer cells
46. A Phase II study of bryostatin 1 in metastatic malignant melanoma
47. NCIC CTG randomized Phase II study of two schedules of bryostatin 1 (NSC339555) in patients with advanced malignant melanoma (IND. 104)
48. Phase II trial of bryostatin-1 in patients with melanoma
49. A sensitive platelet activation-based functional assay for the antileukemic agent bryostatin 1
50. High-performance liquid chromatographic assay for the novel antitumor drug, bryostatin-1, incorporating a serum extraction technique
51. Modulation of resistance to ara-C by bryostatin in fresh blast cells from patients with AML
52. Effects of antisense p21 (WAF1/CIP1/MDA6) expression on the induction of differentiation and drug-mediated apoptosis in human myeloid leukemia cells (HL-60)
53. Sensitization of human breast cancer cells to gemcitabine by bryostatin 1
54. A Phase I trial of weekly sequential bryostatin-1 (BRYO) and paclitaxel in patients with advanced solid tumors
55. Phase I study of bryostatin-1 (NSC 339555) and cisplatin in advanced malignancies